Italian Angels for Growth has invested $2.27 million in Votis, a healthcare startup focused on innovative solutions for diabetic foot syndrome.

Information on the Target

Votis, founded in 2017 in Jerusalem, focuses on critical limb ischemia, which represents the advanced stage of peripheral artery disease. The company's expertise lies in the identification and treatment stratification of diabetic foot syndrome. Globally, over 200 million people are affected by peripheral artery diseases, with Italy alone recording between 7,000 and 8,000 diabetic patients forced into foot amputations each year due to complications from this condition.

The recent investment by Italian Angels for Growth (IAG) not only underscores the potential of Votis but also reflects a commitment to addressing a critical healthcare challenge. The company has developed a cutting-edge device aimed at improving early diagnosis and treatment of this serious condition, thereby reducing preventable amputations.

Industry Overview in Italy

The healthcare sector in Italy has been facing increasing pressure due to an aging population and a rising prevalence of chronic diseases, particularly diabetes.